Chemicals · Fiscal year end Mar 31

ReproCELL Incorporated

4978

株式会社リプロセル

FIGI BBG000K009B44978.T4978 JPCorp. no. 2020001086778

Latest half-year results

First half · fiscal year to 2026-03 · filed 2025-11-13

For the first half of the fiscal year to 2026-03: Revenue ¥1 billion (-26.2% YoY), Ordinary income ¥-0.5 billion, Net income ¥-0.5 billion.

	This period	Year on year
Revenue	¥974m	-26.2%
Ordinary profit	−¥483m	—
Net profit to owners	−¥486m	—

From the securities report on EDINET, which states no forecast. History via /v1/companies/4978/earnings-releases.

Financials

Japan GAAP · consolidated · fiscal year to 2026-03-31

Revenue: ¥2.2bn
Net income: −¥592m
ROE: —
Equity ratio: 91.7%
Dividend / share: —
Employees: 101

Revenue · ¥bn

Net income · ¥m

Fiscal year	Revenue	Net income	Total assets	Net assets	ROE	EPS	Operating CF
2026-03-31	¥2,234m	−¥592m	¥9,652m	¥8,847m	—	¥-6.25	−¥384m
2025-03-31	¥2,979m	¥103m	¥9,671m	¥8,985m	1.2%	¥1.11	¥6m
2024-03-31	¥2,427m	−¥31m	¥9,053m	¥8,312m	—	¥-0.37	−¥11m
2023-03-31	¥2,953m	−¥305m	¥8,356m	¥7,575m	—	¥-3.62	−¥141m
2022-03-31	¥2,235m	−¥575m	¥8,095m	¥7,251m	—	¥-7.57	−¥246m

Indicators

Computed by us from filings · fiscal year to 2026-03-31

Metric	Value	Percentile among listed companies
ROE, %	—	—
Ordinary margin	-0.2603	2.4
Equity ratio, %	91.7	99.1
Revenue growth	-0.2502	1.8
Net income growth	-6.731	1.7
Operating cash flow / assets	-0.0397	9

Policy-uncertainty measure1.20 Share of the report's text discussing policy-related uncertainty, by policy area. Proprietary text method.

Trade & tariffs 2 Politics & geopolitics 2

Ownership activity 0 filer(s) stated they may make proposals in 365 days; 2 new 5% holder(s) in 180 days; net stake change +5.36pt in 90 days; 0.0% held by other listed companies.

Results wording balance: +1.00. Proprietary text method; it describes the wording only and does not interpret context.

Via /v1/companies/4978/indicators. Descriptive figures, not a rating and not investment advice.

From other filings

As the company states them

Internal control, 2026-06-26: see filing 上記の評価の結果、当連結会計年度末日時点において、当社の財務報告に係る内部統制は有効であると判断しました。 Filing

Segments, votes and tender offers

Stated in EDINET filings

Segments: Research Support Business, Medical Business. /v1/companies/4978/segments

Latest voting result: 2026-06-26 · 資本準備金の額の減少及び剰余金の処分の件 · passed. /v1/companies/4978/voting

Ownership changes

All companies →

2026-10-27

Increase+4.11pt

Heights Capital Management, Inc. raised holdings in ReproCELL Incorporated (4978) to 12.36% from 8.25%.

S100ZA4GFiler profile Original filing (PDF, Japanese)
2026-10-27

Threshold

Holdings of Heights Capital Management, Inc. in ReproCELL Incorporated (4978) moved above 10% (8.25% -> 12.36%).

S100ZA4GFiler profile Original filing (PDF, Japanese)
2026-10-22

Below 5%−2.46pt

BofA Securities Japan Co Ltd cut holdings in ReproCELL Incorporated (4978) to 2.58% from 5.04%, below the 5% threshold.

S100Z94QFiler profile Original filing (PDF, Japanese)
2026-09-25

New 5% stake

BofA Securities Japan Co Ltd disclosed a 5.04% stake in ReproCELL Incorporated (4978), crossing the 5% reporting threshold.

S100Z38EFiler profile Original filing (PDF, Japanese)
2026-09-14

Decrease−2.60pt

Heights Capital Management, Inc. reduced holdings in ReproCELL Incorporated (4978) to 8.25% from 10.85%.

S100Z1VAFiler profile Original filing (PDF, Japanese)
2026-09-14

Threshold

Holdings of Heights Capital Management, Inc. in ReproCELL Incorporated (4978) moved below 10% (10.85% -> 8.25%).

S100Z1VAFiler profile Original filing (PDF, Japanese)
2026-09-10

Increase+4.90pt

Heights Capital Management, Inc. raised holdings in ReproCELL Incorporated (4978) to 10.85% from 5.95%.

S100Z1C1Filer profile Original filing (PDF, Japanese)
2026-09-10

Threshold

Holdings of Heights Capital Management, Inc. in ReproCELL Incorporated (4978) moved above 10% (5.95% -> 10.85%).

S100Z1C1Filer profile Original filing (PDF, Japanese)
2026-09-07

Below 5%−1.14pt

BofA Securities Japan Co Ltd cut holdings in ReproCELL Incorporated (4978) to 4.19% from 5.33%, below the 5% threshold.

S100Z0ACFiler profile Original filing (PDF, Japanese)
2026-08-24

Amendment+2.75pt

Heights Capital Management, Inc. filed a correction to a 5% report on ReproCELL Incorporated (4978).

S100YY7EFiler profile Original filing (PDF, Japanese)

Trades by 5% holders

From the 60-day trade tables in 5% reports

Bought SoldHover a dot for the trade

Holder	Period	Net shares	Net % of shares	Avg. filed price	Range
Heights Capital Management, Inc.	2026-06-11 – 2026-10-20	+14,160,000	+12.76pt	¥128.86	¥112–149
モルガン・スタンレーMUFG証券株式会社	2023-10-23 – 2024-01-25	+8,543,786	+8.93pt	¥189.31	¥160–244
Morgan Stanley & Co. International plc	2023-10-23 – 2024-01-25	0	−0.01pt	¥184.97	¥160–243
Morgan Stanley & Co. LLC	2023-10-23 – 2024-01-25	0	0.00pt	—	—
SMBC日興証券株式会社	2021-09-13 – 2021-11-30	-4,435,400	−5.28pt	¥244.96	¥224–294

Net shares and the average are our calculations. Prices are filed prices as stated by the filer, mostly for off-market trades; they are not market prices. Stock lending, custody transfers and option exercises are excluded from net shares. Every row via /v1/companies/4978/trades.

5% filings

Large shareholding reports on 4978

Filed	Filer	Stake	Change	Stated purpose
2026-10-27	Heights Capital Management, Inc.	12.36%	+4.11pt	pure investment
2026-10-22	BofA Securities Japan Co Ltd	2.58%	−2.46pt	—
2026-09-25	BofA Securities Japan Co Ltd	5.04%	—	—
2026-09-14	Heights Capital Management, Inc.	8.25%	−2.60pt	pure investment
2026-09-10	Heights Capital Management, Inc.	10.85%	+4.90pt	pure investment
2026-09-07	BofA Securities Japan Co Ltd	4.19%	−1.14pt	—
2026-08-24	Heights Capital Management, Inc.	8.70%	—	pure investment
2026-08-24	Heights Capital Management, Inc.	5.95%	−2.75pt	pure investment
2026-08-19	Heights Capital Management, Inc.	5.95%	−2.75pt	pure investment
2026-08-12	Heights Capital Management, Inc.	8.70%	+5.30pt	pure investment

Cross-shareholdings

From the annual report's status of shareholdings

Listed strategic holdings: 1 issues
Book value: ¥41m
Sold in the year: — — issues
Bought in the year: — — issues
Mutual, both reports: 0
Held by listed cos.: 0

Holds	Book value	Shares vs. prior year	Mutual
Kringle Pharma,Inc. 4884	¥41m	0.0%	no

Purposes, all holdings and mutual flags via /v1/companies/4978/cross-holdings. Share changes include stock splits.

Major shareholders

As of fiscal year end 2026-03-31

Shareholder	Shares	Ratio
individual holder	1,158,950	1.21%
individual holder	1,000,000	1.05%
上田八木短資株式会社	832,400	0.87%
individual holder	828,600	0.87%
STATE STREET BANK AND TRUST COMPANY 505223	728,900	0.76%
株式会社日本生物材料センター	567,600	0.59%
individual holder	500,000	0.52%
individual holder	470,800	0.49%
旭化成酸素株式会社	455,000	0.47%
individual holder	453,900	0.47%

U.S. funds holding 4978

SEC Form N-PORT, reports to 2026-07-31

7 U.S. funds held 1,003,400 shares worth $0.8m.

Fund	Shares	Value	% of fund	As of
State Street(R) SPDR(R) Portfolio Developed World ex-US ETF SPDR INDEX SHARES FUNDS	778,800	$0.6m	0.001%	2026-06-30
THE JAPANESE SMALL COMPANY SERIES DFA INVESTMENT TRUST CO	86,100	$0.1m	0.002%	2026-07-31
State Street(R) SPDR(R) S&P(R) International Small Cap ETF SPDR INDEX SHARES FUNDS	49,900	$0.0m	0.004%	2026-06-30
INTERNATIONAL CORE EQUITY 2 PORTFOLIO DFA INVESTMENT DIMENSIONS GROUP INC	28,500	$0.0m	0.000%	2026-07-31
Dimensional International Core Equity 2 ETF Dimensional ETF Trust	24,500	$0.0m	0.000%	2026-07-31

Up to 25 funds per stock via the API.

Get this as JSON

GET /v1/companies/4978
GET /v1/companies/4978/financials
GET /v1/companies/4978/details
GET /v1/companies/4978/segments
GET /v1/companies/4978/voting
GET /v1/companies/4978/tender-offers
GET /v1/companies/4978/indicators
GET /v1/companies/4978/earnings-releases
GET /v1/events?ticker=4978
GET /v1/companies/4978/trades         
GET /v1/companies/4978/cross-holdings 
GET /v1/companies/4978/brief

Plans from $9 a month · Documentation